Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03194126
Other study ID # LOCAL/2016/VL-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 11, 2018
Est. completion date September 25, 2023

Study information

Verified date October 2023
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Reducing the time patients spend in the labor and delivery room saves money and reduces patient discomfort as well and reducing complications. We will compare two methods for inducing cervical maturation in order to shorten the time taken between administration of drugs and delivery.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date September 25, 2023
Est. primary completion date September 25, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - The patient must have given their free and informed consent and signed the consent form - The patient must be a member or beneficiary of a health insurance plan - The patients is at least 18 years old - Patient with a singleton pregnancy between 14 and 34 weeks gestation with an indication for medical termination due to maternal or fetal problem as validated by pluridisciplinary prenatal diagnosis center. Exclusion Criteria: - The subject is participating in an interventional study or is in a period of exclusion determined by a previous study - The patient is under safeguard of justice - The subject refuses to sign the consent - It is impossible to give the subject informed information - Patient has vaginismus - Patient has a cervix permitting artificial rupture of membrane - Patients taking one of the following treatments, contraindicated for mifepristone: ketoconazole, itraconazole, erythromycin, grapefruit juice, rifampicin, dexamethasone, St John's wort and certain anti-convulsants (phenytoin, phenobarbital, carbamazepine). Patients contraindicated for oxytocine.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Mifepristone + Misoprostol OR oxytocine + laminaria
Three laminaria placed 12 hours prior to administration of misoprostol
Mifepristone + Misoprostol OR oxytocine
standart support

Locations

Country Name City State
France CHU de Montpellier Montpellier
France CHU Nimes Nîmes

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary time taken between administration of 1st dose of drugs and delivery between the two strategies Up to 2 days
Secondary Compare pain experienced by patients between groups scale 0-10 Day 0 - Day 2
Secondary Compare cervix length before administration of Misoprostol OR oxytocine between groups in mm Day 0
Secondary Compare degree of dilation before administration of Misoprostol OR oxytocine between groups in cm Day 0
Secondary Compare time taken between Misoprostol OR oxytocine and delivery between groups hours Day 0 - Day 2
Secondary Rate of delivery between groups 4 hours
Secondary Rate of delivery between groups 6 hours
Secondary Rate of delivery between groups 8 hours
Secondary Rate of delivery between groups 12 hours
Secondary Rate of delivery between groups >12 hours
Secondary Incidence of endometritis between groups Day 0 - Day 2
Secondary Incidence of hemorrhage between groups Day 0 - Day 2
Secondary Patient satisfaction in peripartum between groups Numeric Rating Scale (0-10) Day 2
Secondary Patient anxiety between groups Hospital Anxiety and Depression Scale questionnaire Day 0 - 3 months
Secondary Evaluation of any post-traumatic stress between groups Perinatal post-traumatic stress disorder questionnaire 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT02694198 - Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion N/A
Completed NCT01860521 - Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia N/A
Withdrawn NCT04304365 - Home Follow-up After Medication Abortion N/A
Completed NCT03400358 - Uterocervical Angle in the Pregnancy Termination of Multiparous Women N/A
Recruiting NCT05342467 - Gemeprost Versus Dinoprostone in First Trimester Miscarriages Phase 2
Recruiting NCT03269279 - Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso Phase 3
Completed NCT02381223 - Simplified Medical Abortion Screening: A Pilot Demonstration Project N/A
Recruiting NCT05940233 - Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone N/A
Not yet recruiting NCT03570307 - Fertility and Obstetric Outcomes After Medical Management Versus Surgical Treatment for First-trimester Miscarriage First-trimester Miscarriage N/A
Completed NCT01943279 - Comparison of Telephone Follow-up With In-person Follow-up After Medical Abortion N/A
Not yet recruiting NCT04194658 - Effectiveness of Pretreatment Letrozole Versus Misoprostol Alone in Missed Abortion Phase 2
Completed NCT01966874 - Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days Gestation Phase 2/Phase 3